<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25428" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mycosis Fungoides</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vaidya</surname>
            <given-names>Tanvi</given-names>
          </name>
          <aff>Father Muller MC, Rajiv Gandhi Un of HS.</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Badri</surname>
            <given-names>Talel</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tanvi Vaidya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Talel Badri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25428.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The early identification, diagnosis and management of Mycosis fungoides is imperative in a dermatology out patient setting. This activity reviews the etiolopathogenesis, epidemiology, clinical and histological features, diagnosis and treatment of Mycosis fungoides.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various clinical stages of mycosis fungoides.</p></list-item><list-item><p>Describe the histopathology of mycosis fungoides.</p></list-item><list-item><p>Outline the treatment of mycosis fungoides.</p></list-item><list-item><p>Explain the importance of collaboration and communication among the interprofessional team to ensure mycosis fungoides is appropriately treated thereby improving outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25428&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25428">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25428.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Primary cutaneous lymphomas are the second most common extranodal non-Hodgkin Lymphomas. They may be of either T cell, B cell, or NK cell origin.&#x000a0;Cutaneous T Cell lymphomas (CTCL) comprise a group of heterogeneous lymphomas which clinically differ from systemic lymphomas, even though they might show similar histology.&#x000a0;<xref ref-type="bibr" rid="article-25428.r1">[1]</xref><xref ref-type="bibr" rid="article-25428.r2">[2]</xref><xref ref-type="bibr" rid="article-25428.r3">[3]</xref></p>
        <p>Mycosis fungoides is the most common type of CTCL.&#x000a0;It is a cutaneous lymphoma that originates in the peripheral epidermotropic T-cells, specifically the memory T-cells (CD45RO+), which express the T-cell receptor (TCR) and CD4+&#x000a0;immunophenotype.<xref ref-type="bibr" rid="article-25428.r4">[4]</xref></p>
      </sec>
      <sec id="article-25428.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The cause of mycosis fungoides is unclear. The following are various hypotheses proposed:<xref ref-type="bibr" rid="article-25428.r5">[5]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Genetic and epigenetic abnormalities,&#x000a0;most commonly deletions and translocations involving several different chromosomes or chromosomal segments.<xref ref-type="bibr" rid="article-25428.r6">[6]</xref><xref ref-type="bibr" rid="article-25428.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Environmental and occupational exposure to solvents and chemicals has been implicated in the etiology of the disease.&#x000a0;<xref ref-type="bibr" rid="article-25428.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>An infectious etiology that&#x000a0;is of human T-lymphotropic virus Type 1 has been suggested, but conclusive evidence has still not been found.&#x000a0;<xref ref-type="bibr" rid="article-25428.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Cytokines such as IL-2 and IL-4 may play a role, as they show higher levels in patients with mycosis fungoides and Sezary syndrome.<xref ref-type="bibr" rid="article-25428.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Mycosis fungoides has an incidence of around 6 cases per million per year in Europe and the United States. This accounts for 4% of all non-Hodgkin lymphoma cases. It is more common in adults over 50 years of age, with a male:female ratio between 1.6 and 2. The disease is more common amongst Blacks than Caucasians or Asians.<xref ref-type="bibr" rid="article-25428.r11">[11]</xref><xref ref-type="bibr" rid="article-25428.r12">[12]</xref></p>
      </sec>
      <sec id="article-25428.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Among the cutaneous lymphomas, nearly two-thirds are of the T cell type. The most common immunophenotype is CD4 positive. In mycosis fungoides, there is a clonal expansion of CD4 cells that often lack the normal T cell antigens like CD7, CD5 or CD 2. These cells are attracted towards the skin by keratinocytes. As the cells accumulate in the dermis, they cluster around the langerhan&#x000a0;cells- which is known as Pautrier microabscesses. Some of the malignant cells travel to the local lymph nodes and then pass into the bloodstream where they circulate with other CLA-positive T cells.<xref ref-type="bibr" rid="article-25428.r13">[13]</xref><xref ref-type="bibr" rid="article-25428.r14">[14]</xref></p>
      </sec>
      <sec id="article-25428.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology of mycosis fungoides varies within stages of the disease. Superficial lymphoid infiltrate, epidermotropism with absent or rare spongiosis spongiosis,&#x000a0;and lymphoid atypia are the predominant features.<xref ref-type="bibr" rid="article-25428.r4">[4]</xref><xref ref-type="bibr" rid="article-25428.r15">[15]</xref><xref ref-type="bibr" rid="article-25428.r16">[16]</xref></p>
        <list list-type="order">
          <list-item>
            <p><bold>Patch stage:&#x000a0;</bold>In the early patch stage. it may be difficult to diagnose as infiltrates may be very scant. In more established patches, a lymphocytic infiltrate may be seen around the basal cell layer. The&#x000a0;cells are usually small, well-differentiated lymphocytes with rounded or cerebriform nuclei. The epidermis shows hyperkeratosis and acanthosis. Basal cell degeneration with melanin pigment incontinence may be seen. A dense, mixed perivascular infiltrate may be seen, along with fibrosis of dermal papillae.</p>
          </list-item>
          <list-item>
            <p><bold>Plaque stage:&#x000a0;</bold>In the plaque stage, the epidermis shows acanthosis with a psoriasiform hyperplasia and absent or rare spongiosis. The upper dermis may show a dense, band-like lymphocyte infiltrate with cerebriform nuclei&#x000a0;and prominent epidermotropism. A third of cases may show Pautrier's abscesses.</p>
          </list-item>
          <list-item>
            <p><bold>Tumor stage:&#x000a0;</bold>A loss of epidermotropism may be noticed in the tumor stage. The infiltrate is a dense dermal infiltrate with large cerebriform lymphocytes, with a diminished number of T lymphocytes and dendritic cells.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Immunohistochemistry</bold>
</p>
        <p>Mycosis fungoides tumor cells are characterized by epidermotropic peripheral T lymphocytes whose phenotype is CD2+, CD3+, CD4+, and CD5+. In a minority of patients with mycosis fungoides, T lymphocytes may be CD4- and CD8+, CD4- and CD8-, or CD4+ and CD8+.<xref ref-type="bibr" rid="article-25428.r15">[15]</xref>The loss of CD7 expression can be observed even in the early phases of the disease. However, isolated negativity for CD7 is not a sufficient criterion for diagnosis as it can be shown in inflammatory dermatoses. The loss of CD26 expression seems to be specific to mycosis fungoides neoplastic cells.<xref ref-type="bibr" rid="article-25428.r17">[17]</xref>&#x000a0;</p>
        <p>The immunohistochemical pattern of Sezary syndrome is CD3+, CD4+, CD7-, and CD8-&#x000a0;cells, which&#x000a0;is identical to mycosis fungoides. Immunostaining for MUM-1 (multiple myeloma oncogene) might be used to&#x000a0;differentiate these as it is positive in Sezary syndrome and negative in mycosis fungoides.<xref ref-type="bibr" rid="article-25428.r17">[17]</xref></p>
      </sec>
      <sec id="article-25428.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical presentation of mycosis fungoides varies with the stage of the disease.</p>
        <list list-type="order">
          <list-item>
            <p><bold>Patch stage:&#x000a0;</bold>The earliest lesion seen in mycosis fungoides is an erythematous, or brownish scaly patch, which may show slight atrophy. Single or multiple lesions of&#x000a0;variable diameters and locations develop, often in covered areas and particularly in the gluteal region and on the proximal&#x000a0;thighs. The term sometimes given to them of "plaque parapsoriasis" is a misnomer because the lesions are actually&#x000a0;patches. "Small-plaque" parapsoriasis and "large-plaque" parapsoriasis&#x000a0;are set apart&#x000a0;based on the clinical and histopathological correlation.<xref ref-type="bibr" rid="article-25428.r16">[16]</xref><italic toggle="yes">Small plaque parapsoriasis</italic> lesions are 2 to 6 cm in diameter, located&#x000a0;on the trunk, and do not present atrophy or telangiectasia. Small-plaque parapsoriasis shows minimum potential to become infiltrated or tumoral.<italic toggle="yes">Large-plaque parapsoriasis</italic> presents with lesions that are larger than 6 cm in diameter, with signs of atrophy and poikiloderma. They are&#x000a0;seen on the trunk, gluteal region, proximal extremities and mammary region. The histopathological picture may resemble mycosis fungoides, in fact, large-plaque parapsoriasis does progress to frank mycosis fungoides (i.e infiltrated and/or tumoral lesions) in around 7.5% to 14% of cases.<xref ref-type="bibr" rid="article-25428.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Plaque stage:</bold>&#x000a0;In the plaque stage, lesions now appear larger with evident infiltration, along with the appearance of new lesions. The lesions are annular or horseshoe-shaped with an infiltrated base, raised, well-defined edges and asymmetrical distribution. They may also affect the face and the scalp.&#x000a0;<xref ref-type="bibr" rid="article-25428.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Tumor stage:&#x000a0;</bold>In the tumor stage, erythematous-purplish papules or nodules of larger diameter are seen.&#x000a0;<xref ref-type="bibr" rid="article-25428.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>The frequency of lymph nodal or visceral dissemination increases as the lesions progress from the patch stage to the plaque stage and finally the tumor stage.</p>
        <p>
<bold>Less Common or Rare Clinical Variants</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Bullous/vesicular&#x000a0;lesions<xref ref-type="bibr" rid="article-25428.r20">[20]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Purpuric lesions<xref ref-type="bibr" rid="article-25428.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Poikilodermatous<xref ref-type="bibr" rid="article-25428.r22">[22]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Syringotropic<xref ref-type="bibr" rid="article-25428.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Hypopigmented lesions (mainly in children)<xref ref-type="bibr" rid="article-25428.r24">[24]</xref></p>
          </list-item>
        </list>
        <p><bold>Clinical Variants</bold>&#x000a0;(as described in the WHO-EORTC Classification for Cutaneous Lymphomas)<xref ref-type="bibr" rid="article-25428.r25">[25]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Follicular or folliculotropic&#x000a0;mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Pagetoid reticulosis or Woringer- Kolopp type</p>
          </list-item>
          <list-item>
            <p>Granulomatous slack skin</p>
          </list-item>
        </list>
        <p>
<bold>Sezary syndrome:</bold>
</p>
        <p>Sezary syndrome&#x000a0;constitutes 3% of all cutaneous lymphomas and is characterized by a triad of manifestations: erythroderma with pruritus, lymphadenopathy, and atypical circulating lymphocytes (referred to as Sezary or Lutzner cells). The syndrome is understood as a leukemic phase of T-cell cutaneous lymphomas and bone marrow compromise is rarely found in advanced forms of the disease&#x000a0;only.&#x000a0;Associated clinical manifestations include lagophthalmos, alopecia, palmoplantar hyperkeratosis and onycodystrophy. Sezary Syndrome must be differentiated from erythroderma in mycosis fungoides progression. In the WHO-EORTC classification, MF and SS are listed as seperate diseases.<xref ref-type="bibr" rid="article-25428.r26">[26]</xref><xref ref-type="bibr" rid="article-25428.r27">[27]</xref></p>
      </sec>
      <sec id="article-25428.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Recommended evaluation of the patient with mycosis fungoides/Sezary syndrome:<xref ref-type="bibr" rid="article-25428.r3">[3]</xref><xref ref-type="bibr" rid="article-25428.r28">[28]</xref></p>
        <p>
<bold>Complete Physical Examination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type and extent of skin lesions, with an estimation of body surface area, must be noted. Look for ulceration in the lesions.</p>
          </list-item>
          <list-item>
            <p>For lesions in the tumor stage, evaluate the number, size, and sites of the lesions.</p>
          </list-item>
          <list-item>
            <p>Look for lymphadenopathy and organomegaly.</p>
          </list-item>
        </list>
        <p>
<bold>Skin biopsy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The biopsy site must be chosen carefully. Usually, the most indurated area is selected.</p>
          </list-item>
          <list-item>
            <p>Immunophenotyping for the following markers is performed: CD2, CD3, CD4, CD5, CD7, CD8, and a B-cell marker like CD20.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Evaluation for clonality of TCR gene rearrangement</p>
          </list-item>
        </list>
        <p>
<bold>
<bold>Blood tests</bold>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC, liver function tests, LDH, etc.</p>
          </list-item>
          <list-item>
            <p>TCR gene rearrangement.</p>
          </list-item>
          <list-item>
            <p>Abnormal lymphocyte evaluation may be performed by Sezary cell count with the determination of the absolute number of Sezary cells and flow cytometry.</p>
          </list-item>
        </list>
        <p>
<bold>
<bold>
<bold>Radiologic tests</bold>
</bold>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest X-rays, ultrasounds of peripheral nodal groups, chest CTs, fluorodeoxyglucose (FDG)-PET scans, and MRIs may be performed to evaluate for any potential lymphadenopathy or visceral involvement, depending upon the stage of the disease.</p>
          </list-item>
        </list>
        <p>
<bold>
<bold>
<bold>
<bold>Lymph Node Biopsy</bold>
</bold>
</bold>
</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In clinically suspicious lymph nodes, such as firm, irregular, or fixed nodes, or large nodes of diameter greater than or equal to 1.5 cm in diameter, an excisional biopsy may be performed. It is performed from the largest draining lymph node or as guided by an FDG-PET, the node with the highest standardized uptake value (SUV).</p>
          </list-item>
          <list-item>
            <p>Cervical lymph nodes are the preferred sites, followed by axillary and then inguinal. The biopsy specimen is analyzed for histopathological examination, flow cytometry, and T-cell receptor gene rearrangement.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Early stage:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with early-stage mycosis fungoides (IIA or below), the various treatment options are topical corticosteroids, topical nitrogen mustards (mechlorethamine, HN2), topical bexarotene, imiquimod, psoralen-ultraviolet A (PUVA) therapy or ultraviolet B (UVB) therapy.&#x000a0; Local radiation therapy may be used for localized lesions (such as in pagetoid reticulosis).&#x000a0;<xref ref-type="bibr" rid="article-25428.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>For patients with highly symptomatic, generalized thickened plaques in whom a prompt response is needed, the recommendation is total skin electron beam therapy (TSEBT) or skin-directed therapies in combination with systemic therapies rather than HN2 or UVB alone.&#x000a0;<xref ref-type="bibr" rid="article-25428.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Systemic therapies, such as retinoids or interferons, histone deacetylase (HDAC) inhibitors, or low-dose methotrexate&#x000a0;are used if skin-directed therapies fail, if skin symptoms are&#x000a0;extensive/severe,&#x000a0;or if patients have a worse prognostic profile such as folliculotropic mycosis fungoides, large cell transformation, or early blood involvement.&#x000a0;<xref ref-type="bibr" rid="article-25428.r30">[30]</xref><xref ref-type="bibr" rid="article-25428.r31">[31]</xref><xref ref-type="bibr" rid="article-25428.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Advanced Stage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced stage (IIB to IV) mycosis fungoides is a heterogeneous group that encompasses those patients that present with extracutaneous disease or advanced skin lesions (e.g., tumors). It&#x000a0;is often a chronic or persistent disease with a relapsing course. The main goals of therapy are long-term disease control, prompt symptom relief, and management of life-threatening (aggressive) disease.<xref ref-type="bibr" rid="article-25428.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>For most patients with cutaneous tumors involving a limited percent body surface area (typically less than 10%), treatment with localized radiation to the tumors plus skin-directed therapy as needed for concurrent&#x000a0;patch/plaque&#x000a0;disease is recommended.<xref ref-type="bibr" rid="article-25428.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>For patients with generalized tumors, total skin electron beam therapy (TSEBT) or systemic therapies are acceptable treatment options. TSEBT can be followed by other skin-directed therapies or systemic therapies to prolong response duration.&#x000a0;<xref ref-type="bibr" rid="article-25428.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>For more extensive disease, combinations of skin-directed therapies and systemic therapies are used. The various systemic options available include methotrexate, bexarotene, targeted immunotherapy (such as alemtuzumab), polychemotherapy, etc.<xref ref-type="bibr" rid="article-25428.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with disease&#x000a0;that is&#x000a0;difficult to control should be considered for allogeneic hematopoietic cell transplantation with curative intent.<xref ref-type="bibr" rid="article-25428.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is easy to confuse mycosis fungoides for&#x000a0;common skin disorders such as eczema, psoriasis, parapsoriasis, photodermatitis, or drug reactions.&#x000a0;The important differentials to keep in mind include:<xref ref-type="bibr" rid="article-25428.r36">[36]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Atopic dermatitis, contact dermatitis, drug eruptions, or erythrodermic psoriasis, all of which may cause pruritis and erythroderma resembling mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Sezary syndrome which may resemble erythrodermic mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Other lymphomas such as subcutaneous panniculitis-like T cell lymphoma, primary cutaneous anaplastic large cell lymphoma, cutaneous gamma/delta T cell lymphoma, or cutaneous B cell lymphoma.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The standard staging system for mycosis fungoides was the TNMB system, which was the strongest prognostic indicator for mycosis fungoides. Olsen et al. (2007) published the staging norms of mycosis fungoides and SS as a result of the ISCL-EORTC discussions, and modified the existing TNMB staging system&#x000a0;in view of&#x000a0;advances in cellular and molecular biology in diagnostic methods, as given below.<xref ref-type="bibr" rid="article-25428.r37">[37]</xref></p>
        <p>
<bold>Skin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>T1:&#x000a0;Limited patches,&#x000a0;papules, and/or plaques<bold>&#x000a0;</bold>covering less than 10% of the skin surface. May further stratify into T1a&#x000a0;(patch only) vs. T1b&#x000a0;(plaque +/- patch).</p>
          </list-item>
          <list-item>
            <p>T2:&#x000a0;Patches, papules or plaques covering 10% or more of the skin surface. May further stratify into T2a&#x000a0;(patch only) vs. T2b&#x000a0;(plaque +/- patch).</p>
          </list-item>
          <list-item>
            <p>T3:&#x000a0;One or more tumors<bold>&#x000a0;</bold>(1 cm or more in diameter)</p>
          </list-item>
          <list-item>
            <p>T4:&#x000a0;Confluence of erythema covering 80% or more of body surface area</p>
          </list-item>
        </list>
        <p>
<bold>Lymph Nodes</bold>
</p>
        <p>N0:&#x000a0;No clinically abnormal peripheral lymph nodes; biopsy not required</p>
        <p>N1:&#x000a0;Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0-2</p>
        <list list-type="bullet">
          <list-item>
            <p>N1a:&#x000a0;Clone negative (A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene)</p>
          </list-item>
          <list-item>
            <p>N1b:&#x000a0;Clone positive</p>
          </list-item>
        </list>
        <p>N2:&#x000a0;Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3</p>
        <list list-type="bullet">
          <list-item>
            <p>N2a:&#x000a0;Clone negative</p>
          </list-item>
          <list-item>
            <p>N2b:&#x000a0;Clone positive</p>
          </list-item>
        </list>
        <p>N3:&#x000a0;Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3 to 4 or NCI LN4; clone positive or negative</p>
        <p>Nx:&#x000a0;Clinically abnormal peripheral lymph nodes; no histologic confirmation</p>
        <p>
<bold>Visceral</bold>
</p>
        <p>M0:&#x000a0;No visceral organ involvement</p>
        <p>M1:&#x000a0;Visceral involvement (must have pathology confirmation&#x000a0;and organ involved should be specified)</p>
        <p>
<bold>Blood</bold>
</p>
        <p>B0:&#x000a0;Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells</p>
        <list list-type="bullet">
          <list-item>
            <p>B0a:&#x000a0;Clone negative</p>
          </list-item>
          <list-item>
            <p>B0b:&#x000a0;Clone positive</p>
          </list-item>
        </list>
        <p>B1:&#x000a0;Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2</p>
        <list list-type="bullet">
          <list-item>
            <p>B1a:&#x000a0;Clone negative</p>
          </list-item>
          <list-item>
            <p>B1b:&#x000a0;Clone positive</p>
          </list-item>
        </list>
        <p>B2:&#x000a0;High blood tumor burden: 1000/microL or more Sezary cells&#x000a0;with positive clone</p>
      </sec>
      <sec id="article-25428.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of mycosis fungoides and Sezary syndrome is variable. The TNMB staging&#x000a0;is the strongest prognostic factor.&#x000a0;The following factors may be associated with a poor prognosis:<xref ref-type="bibr" rid="article-25428.r5">[5]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Presence of extracutaneous disease (stage IV),</p>
          </list-item>
          <list-item>
            <p>Older age (greater than 60),</p>
          </list-item>
          <list-item>
            <p>Presence of large cell transformation (LCT), and</p>
          </list-item>
          <list-item>
            <p>Increased LDH</p>
          </list-item>
          <list-item>
            <p>Folliculotropic mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Tumor distribution at diagnosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s13" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Marked pruritus</p>
          </list-item>
          <list-item>
            <p>Lymphadenopathy</p>
          </list-item>
          <list-item>
            <p>Onychodystrophy</p>
          </list-item>
          <list-item>
            <p>Panniculitis</p>
          </list-item>
          <list-item>
            <p>Skin ulcers</p>
          </list-item>
          <list-item>
            <p>Scaring alopecia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25428.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of mycosis fungoides is best done with an interprofessional team of healthcare workers that includes an oncologist, internist, dermatologist, nurses, pharmacists, and social workers. The disorder has no cure, and the aim is to improve the quality of life. The patient should be encouraged to use ample moisturizer to prevent skin dryness and pruritus. The patient should be told to avoid the sun and wear long-sleeved garments when going out. A cool humidified environment is highly recommended. The patient should also be educated about the other treatment options like irradiation, Photodynamic therapy and UV light treatment enhanced with psoralen. Finally, the patient should be seen by a dietitian as many people develop moderate nausea from the treatment and lose significant weight. A&#x000a0;high-calorie&#x000a0;diet with regular exercise is recommended. <xref ref-type="bibr" rid="article-25428.r38">[38]</xref><xref ref-type="bibr" rid="article-25428.r35">[35]</xref>(Level V)</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Mycosis fungoides is an incurable disorder unless the patient has very&#x000a0;early stage disease. The mortality and morbidity increase as the tumor advances. While early-stage patients have a 95% survival over ten years, those who advanced cancer only have a 3-4 year survival. Those with the advanced extra-cutaneous disease only have a survival of fewer than 18 months. Poor prognostic factors include male gender, advanced age, and elevated LDH.<xref ref-type="bibr" rid="article-25428.r39">[39]</xref><xref ref-type="bibr" rid="article-25428.r33">[33]</xref> (Level V)</p>
      </sec>
      <sec id="article-25428.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25428&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25428">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/mycosis-fungoides/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25428">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25428/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25428">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25428.s16">
        <fig id="article-25428.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Mycosis Fungoides <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mycosis__fungoides" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25428.s17">
        <title>References</title>
        <ref id="article-25428.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scarisbrick</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Quaglino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Papadavid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hodak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Servitje</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ortiz-Romero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patsatsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guenova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nikolaou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tomasini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amitay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Prag Naveh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ram-Wolff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alberti-Violetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stranzenbach</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gargallo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Muniesa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koletsa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jonak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porkert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitteldorf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Combalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marschalko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Csomor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szepesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cozzio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grandi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pham-Ledard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wobser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geissinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wehkamp</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weichenthal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cowan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wachsmuth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trautinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Latzka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vydianath</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amel-Kashipaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marinos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oikonomidi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stratigos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vignon-Pennamen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Climent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gonzalez-Barca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Georgiou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Senetta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vakeva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ranki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busschots</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hauben</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bervoets</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woei-A-Jin</surname>
                <given-names>FJSH</given-names>
              </name>
              <name>
                <surname>Matin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weatherhead</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frew</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bayne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dunnill</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arumainathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Azurdia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benstead</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Twigger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rieger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanches</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Miyashiro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Akilov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Damasco</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Querfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Folkes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klemke</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Enz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quint</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Geskin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Evison</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.</article-title>
            <source>Br J Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>181</volume>
            <issue>2</issue>
            <fpage>350</fpage>
            <page-range>350-357</page-range>
            <pub-id pub-id-type="pmid">30267549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karakousis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Disease site as a prognostic factor for mycosis fungoides: an analysis of 2428 cases from the US National Cancer Database.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>May</month>
            <volume>185</volume>
            <issue>3</issue>
            <fpage>592</fpage>
            <page-range>592-595</page-range>
            <pub-id pub-id-type="pmid">30216417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prince</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Querfeld</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Integrating novel systemic therapies for the treatment of mycosis fungoides and S&#x000e9;zary syndrome.</article-title>
            <source>Best Pract Res Clin Haematol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>322</fpage>
            <page-range>322-335</page-range>
            <pub-id pub-id-type="pmid">30213403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hossain</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jennings</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knoblauch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gochoco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chervoneva</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Alpdogan</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sahu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoides.</article-title>
            <source>Chin Clin Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">30818957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>HLJ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EST</given-names>
              </name>
              <name>
                <surname>Tee</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Boey</surname>
                <given-names>JJJ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>MBY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and prognostic factors for mycosis fungoides and S&#x000e9;zary syndrome in a multi-ethnic Asian cohort: a 12-year review.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>8</issue>
            <fpage>1513</fpage>
            <page-range>1513-1521</page-range>
            <pub-id pub-id-type="pmid">30801779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergallo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dapr&#x000e0;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ponti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calvi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Novelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quaglino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Galliano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fierro</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>DNA from Human Polyomaviruses, MWPyV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas.</article-title>
            <source>Anticancer Res</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>4111</fpage>
            <page-range>4111-4114</page-range>
            <pub-id pub-id-type="pmid">29970537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e4;is&#x000e4;nen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Koskenmies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fyhrquist</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Keinonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000e4;kisalo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>V&#x000e4;kev&#x000e4;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pitk&#x000e4;nen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ranki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hedman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>S&#x000f6;derlund-Venermo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutavirus DNA in Malignant and Nonmalignant Skin of Cutaneous T-Cell Lymphoma and Organ Transplant Patients but Not of Healthy Adults.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>May</month>
            <day>17</day>
            <volume>68</volume>
            <issue>11</issue>
            <fpage>1904</fpage>
            <page-range>1904-1910</page-range>
            <pub-id pub-id-type="pmid">30239652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slodownik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moshe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sprecher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Occupational mycosis fungoides - a case series.</article-title>
            <source>Int J Dermatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>733</fpage>
            <page-range>733-737</page-range>
            <pub-id pub-id-type="pmid">28255994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blaizot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ouattara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fauconneau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pham-Ledard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Infectious events and associated risk factors in mycosis fungoides/S&#x000e9;zary syndrome: a retrospective cohort study.</article-title>
            <source>Br J Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>179</volume>
            <issue>6</issue>
            <fpage>1322</fpage>
            <page-range>1322-1328</page-range>
            <pub-id pub-id-type="pmid">30098016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujii</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>198</fpage>
            <pub-id pub-id-type="pmid">29915722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amorim</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Niemeyer-Corbellini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Quintella</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cuzzi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical and epidemiological profile of patients with early stage mycosis fungoides.</article-title>
            <source>An Bras Dermatol</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>546</fpage>
            <page-range>546-552</page-range>
            <pub-id pub-id-type="pmid">30066762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amorim</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Niemeyer-Corbellini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Quintella</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cuzzi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hypopigmented mycosis fungoides: a 20-case retrospective series.</article-title>
            <source>Int J Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>306</fpage>
            <page-range>306-312</page-range>
            <pub-id pub-id-type="pmid">29318586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rogojanu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jerney</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Erhart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dohnal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kitzw&#x000f6;gerer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trautinger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mast Cells Are Abundant in Primary Cutaneous T-Cell Lymphomas: Results from a Computer-Aided Quantitative Immunohistological Study.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>e0163661</fpage>
            <pub-id pub-id-type="pmid">27893746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tard&#x000ed;o</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khedaoui</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Indeterminate Cell Histiocytosis and Mycosis Fungoides: A Hitherto Unreported Association.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>461</fpage>
            <page-range>461-463</page-range>
            <pub-id pub-id-type="pmid">30024412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abbade</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Mycosis fungoides and S&#x000e9;zary syndrome: clinical, histopathological and immunohistochemical review and update.</article-title>
            <source>An Bras Dermatol</source>
            <year>2012</year>
            <season>Nov-Dec</season>
            <volume>87</volume>
            <issue>6</issue>
            <fpage>817</fpage>
            <page-range>817-28; quiz 829-30</page-range>
            <pub-id pub-id-type="pmid">23197199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vonderheid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haeffner</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Glusac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guitart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lessin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smoller</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Telang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwatsuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Obitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Takigawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>GS</given-names>
              </name>
              <collab>International Society for Cutaneous Lymphoma</collab>
            </person-group>
            <article-title>Defining early mycosis fungoides.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>1053</fpage>
            <page-range>1053-63</page-range>
            <pub-id pub-id-type="pmid">16310068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immunocytochemistry and the diagnosis of cutaneous lymphoma.</article-title>
            <source>Histopathology</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-90</page-range>
            <pub-id pub-id-type="pmid">20055906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nestle</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Doebbeling</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Haeffner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis.</article-title>
            <source>Arch Dermatol</source>
            <year>1996</year>
            <month>May</month>
            <volume>132</volume>
            <issue>5</issue>
            <fpage>567</fpage>
            <page-range>567-72</page-range>
            <pub-id pub-id-type="pmid">8624155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keehn</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Belongie</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Shistik</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fenske</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis, staging, and treatment options for mycosis fungoides.</article-title>
            <source>Cancer Control</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-11</page-range>
            <pub-id pub-id-type="pmid">17387295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowman</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sanusi</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Mycosis fungoides bullosa: report of a case and review of the literature.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>934</fpage>
            <page-range>934-9</page-range>
            <pub-id pub-id-type="pmid">11712043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Georgala</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katoulis</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Symeonidou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Georgala</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vayopoulos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Persistent pigmented purpuric eruption associated with mycosis fungoides: a case report and review of the literature.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-4</page-range>
            <pub-id pub-id-type="pmid">11451328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindae</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Poikilodermatous mycosis fungoides and atrophic large-plaque parapsoriasis exhibit similar abnormalities of T-cell antigen expression.</article-title>
            <source>Arch Dermatol</source>
            <year>1988</year>
            <month>Mar</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>366</fpage>
            <page-range>366-72</page-range>
            <pub-id pub-id-type="pmid">3257858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zelger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sepp</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weyrer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;newald</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zelger</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Syringotropic cutaneous T-cell lymphoma: a variant of mycosis fungoides?</article-title>
            <source>Br J Dermatol</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>130</volume>
            <issue>6</issue>
            <fpage>765</fpage>
            <page-range>765-9</page-range>
            <pub-id pub-id-type="pmid">8011503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Shabrawi-Caelen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>McCalmont</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>450</fpage>
            <page-range>450-7</page-range>
            <pub-id pub-id-type="pmid">11914622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diaz-Perez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>WHO-EORTC classification for cutaneous lymphomas.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>May</month>
            <day>15</day>
            <volume>105</volume>
            <issue>10</issue>
            <fpage>3768</fpage>
            <page-range>3768-85</page-range>
            <pub-id pub-id-type="pmid">15692063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopez</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Geskin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>805</fpage>
            <page-range>805-819</page-range>
            <pub-id pub-id-type="pmid">30173294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <collab>PDQ Adult Treatment Editorial Board</collab>
            <chapter-title>Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ&#x000ae;): Health Professional Version</chapter-title>
            <source>PDQ Cancer Information Summaries [Internet]</source>
            <publisher-name>National Cancer Institute (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>8</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">26389288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wain</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Consuegra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fernandez-Pe&#x000f1;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Management of cutaneous T-cell lymphomas: Established and emergent therapies.</article-title>
            <source>Australas J Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-208</page-range>
            <pub-id pub-id-type="pmid">30809800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dairi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dadban</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnault</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chaby</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Localized mycosis fungoides treated with laser-assisted photodynamic therapy: a case series.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>930</fpage>
            <page-range>930-932</page-range>
            <pub-id pub-id-type="pmid">30825216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jantschitsch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Photopheresis-An Overview.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>236</fpage>
            <pub-id pub-id-type="pmid">30211164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brazzelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bernacca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barruscotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolcato</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Michelerio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomasini</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Photo-photochemotherapy in Juvenile-onset Mycosis Fungoides: A Retrospective Study on 9 Patients.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-37</page-range>
            <pub-id pub-id-type="pmid">30130275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Photiou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van der Weyden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miles Prince</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and S&#x000e9;zary Syndrome.</article-title>
            <source>Curr Oncol Rep</source>
            <year>2018</year>
            <month>Mar</month>
            <day>23</day>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">29572582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jang</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution.</article-title>
            <source>Radiat Oncol J</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-162</page-range>
            <pub-id pub-id-type="pmid">29983036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alpdogan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kartan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapy of cutaneous T-cell lymphoma (CTCL).</article-title>
            <source>Chin Clin Oncol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">30818958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Villasenor-Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Multidisciplinary Management of Mycosis Fungoides/S&#x000e9;zary Syndrome.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-243</page-range>
            <pub-id pub-id-type="pmid">28540671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olisova</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>Grekova</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Varshavsky</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Gorenkova</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Alekseeva</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Zaletaev</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Sydikov</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>[Current possibilities of the differential diagnosis of plaque parapsoriasis and the early stages of mycosis fungoides].</article-title>
            <source>Arkh Patol</source>
            <year>2019</year>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-17</page-range>
            <pub-id pub-id-type="pmid">30830099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vonderheid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zackheim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estrach</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lamberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ranki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pittelkow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bernengo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Trautinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <collab>ISCL/EORTC</collab>
            </person-group>
            <article-title>Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC).</article-title>
            <source>Blood</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>1713</fpage>
            <page-range>1713-22</page-range>
            <pub-id pub-id-type="pmid">17540844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Brien</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lawrentschuk</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Blueprint unknown: a case for multidisciplinary management of advanced penile mycosis fungoides.</article-title>
            <source>Can J Urol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>9139</fpage>
            <page-range>9139-9144</page-range>
            <pub-id pub-id-type="pmid">29260643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25428.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebowitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flores</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pulitzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kheterpal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Myskowski</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and S&#x000e9;zary syndrome: a retrospective analysis of 174 patients.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-114</page-range>
            <pub-id pub-id-type="pmid">30176169</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
